9 innovative solutions will receive support to facilitate their integration into the health system
The second INNOPASS call has selected initiatives in areas such as precision oncology, chronic kidney disease, epilepsy, chronic wounds, and structural cardiology.

A total of nine initiatives have been selected in the second INNOPASS call and will receive the Innovation Passport, giving them access to a pathway of personalized support for one year to advance their fit with and potential integration into the public health system.
The selected proposals are CarboSign4CANCER, Cancer Genome Interpreter, EPISERAS, FIBROKIT, KFRE and KLINRISK, Woundify, WIVI Vision, CORAAL and NerveCheck. Developed by research centers and companies in the BioRegion, they address a range of needs, from screening and diagnosis to disease monitoring and clinical decision support.
INNOPASS is part of the Program for Access of Innovation to the Catalan Health System (PASS), led by the Department of Health and Biocat, with participation from the Catalan Health Service (CatSalut), the Agency for Health Quality and Assessment of Catalonia (AQuAS), the TIC Salut i Social Foundation, and the Institute of Diagnostic Imaging. The program works to connect the ecosystem’s innovative capacity with the needs of the health system and facilitate the adoption of solutions with the potential to make an impact.
The selected initiatives will receive scientific, technological, and strategic support and will be able to connect with key stakeholders in the ecosystem and the health system. This support will help them address areas such as clinical evidence, alignment with care pathways, technological integration, and implementation options.
The proposals were selected for their level of technological maturity and potential clinical, organizational, social, or environmental impact, in line with the priority areas identified by CatSalut. The call also incorporates three cross-cutting priorities: putting people at the center, integrating a gender perspective, and ensuring the economic, social, and environmental sustainability of the solutions. A total of 38 initiatives were submitted.
The nine selected innovative solutions
Hospital del Mar Research Institute is developing an early cancer detection test based on a signature of seven blood metabolites and artificial intelligence algorithms. The initial indication is pancreatic cancer, with the potential to extend the model to other tumors.
The IRB Barcelona project brings the Cancer Genome Interpreter platform into clinical practice. The tool helps interpret genomic variants in tumors, identify biomarkers, and provide information on potential treatment options in precision oncology.
Neuraxpharm has developed EPISERAS, an in-ear device that uses artificial intelligence to analyze brain activity and provide advance warning of a potential epileptic seizure. The solution aims to give people with drug-resistant epilepsy and their caregivers time to respond.
Debios is developing FIBROKIT, a noninvasive urine test to assess kidney fibrosis. The test aims to help identify and monitor the progression of chronic kidney disease.
Roche Diagnostics presents two digital algorithms to estimate the risk of chronic kidney disease progression: KFRE and KLINRISK. These tools can help personalize monitoring and prioritize referrals to nephrology.
Healthivity’s Woundify platform uses computer vision to document, measure, and monitor chronic wounds. It aims to support care teams and facilitate more structured follow-up.
e-HEALTH TECHNICAL SOLUTIONS SL has developed the digital product WIVI Vision, which offers interactive tests and personalized exercises to assess and train visual skills and support the detection and monitoring of changes in visual function.
Virtest Technologies has developed CORAAL, a tool that combines artificial intelligence and physical simulation to reconstruct a patient’s anatomy and plan device implantation in structural cardiology.
Phi Med Europe has created NerveCheck, a device that quantitatively measures thermal and vibration sensitivity to support screening and monitoring of peripheral neuropathies, particularly in people with diabetes or at risk of foot injuries.
A new call to connect innovation with the needs of the system
The first INNOPASS call selected 10 innovative solutions from the BioRegion, which received the Innovation Passport and a personalized support pathway. The second edition continues this work to help mature solutions advance their fit with the health system.
The program provides the selected initiatives with support to work through the steps needed to progress toward potential adoption in care pathways.
